Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Clinical Program Recap For HPV-Associated Illnesses 0 comments
    Jul 1, 2013 5:35 PM | about stocks: ADXS

    Roughly 12,340 people will be diagnosed with cervical cancer this year, according to American Cancer Society estimates. Development-stage biotech company Advaxis is focused on developing immunotherapies for various cancers and infectious disease, including cervical cancer.

    The company's ADXS-HPV (ADXS11-001) is a therapeutic vaccine for the treatment of women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection, which is also related to a number of cancers, including other genital cancers and some head and neck cancers.

    Advaxis' ADXS11-001 vaccine is currently being developed to help the body build an effective immune response to kill tumor cells. The candidate is undergoing phase II clinical trials for the purpose of evaluating side effects and the efficacy of the vaccine in patients with persistent or recurrent cervical cancer.

    As of May 17, 2013, Advaxis had completed enrollment and 110 patients had received 264 doses of ADXS11-001. The company reported final 12-month overall survival at 36 percent with a current 18-month survival of 22 percent, marking the best results yet for this study. The most recent data compare to data from the last update at 33 percent and 17 percent, respectively.

    The company estimates primary completion of the phase II study in October 2013.

    Advaxis' clinical pipeline also includes: ADXS-PSA, currently in pre-clinical development for the treatment of prostate cancer; and ADXS-cHER2, currently in pre-clinical development for the treatment of HER2 over-expressing cancers, and in a phase 1 veterinary trial for canine osteosarcoma in large breed companion dogs.

    For more information, visit advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.